Original Research

Calcified Tissue International

, Volume 89, Issue 4, pp 265-270

Risk of Newly Diagnosed Type 2 Diabetes Is Reduced in Users of Alendronate

  • Peter VestergaardAffiliated withDepartment of Endocrinology and Internal Medicine, The Osteoporosis Clinic, Aarhus University Hospital THG Email author 

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access


To study the risk of developing type 1 (T1D) or type 2 (T2D) diabetes among users of drugs against osteoporosis compared to nonusers. Nationwide cohort study in Denmark with all users of drugs against osteoporosis (n = 103,562) as exposed and three age- and sex-matched nondiabetic control subjects (n = 310,683) randomly selected from the background population. The main outcome variable was an incident diagnosis of diabetes after the baseline date. Among users of alendronate, etidronate, and raloxifene, no change in the risk of T1D was observed. However, the risk of developing T2D was reduced with all three drugs (alendronate: hazard ratio [HR] = 0.71, 95% confidence interval [CI] 0.59–0.85, etidronate: HR = 0.77, 95% CI 0.69–0.86, raloxifene: HR = 0.46, 95% CI 0.25–0.87). For alendronate, a dose-dependent risk reduction was observed (≥1 defined daily dose (DDD) per day: HR = 0.22, 95% CI 0.12–0.41, P for trend <0.01), while this was not the case for etidronate and raloxifene. Antiresorptive drugs do not seem associated with an increased risk of diabetes, but they may perhaps provide a protective effect related to the suppression of bone turnover. However, further studies are needed.


Alendronate Bisphosphonate Etidronate Raloxifene Type 1 diabetes Type 2 diabetes